Limitations on how testosterone is used and marketed remain under consideration at the Food and Drug Administration following a recent advisory panel recommendation.

The Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee made two recommendations to the agency at a joint meeting […]